Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 16/20 | 0.43 |
| ▸ | SCN1A | P35498 | 12/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19613809 | 0.94 | SCN8A (0.43) | SCN8ASCN1AMEN1KMT2A | |
| SCHEMBL29447402 | 0.94 | SCN8A (0.43) | SCN8ASCN1AMEN1KMT2A | |
| SCHEMBL19613807 | 0.94 | SCN8A (0.43) | SCN8ASCN1AMEN1KMT2A | |
| SCHEMBL19627767 | 0.91 | SCN8A (0.42) | SCN8ASCN1A | |
| SCHEMBL19627747 | 0.86 | PIK3CA (0.37) | KAT6AKAT5 | |
| SCHEMBL19614254 | 0.86 | SCN8A (0.46) | SCN8ASCN1A | |
| SCHEMBL19614252 | 0.86 | SCN8A (0.46) | SCN8ASCN1A | |
| SCHEMBL28521482 | 0.85 | SCN8A (0.41) | SCN8ASCN1AMEN1KMT2A | |
| SCHEMBL19628753 | 0.85 | SCN8A (0.41) | SCN8ASCN1AMEN1KMT2A | |
| SCHEMBL29447384 | 0.85 | SCN8A (0.41) | SCN8ASCN1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | SCN8A 14/4885SCN1A 1/4885LMNA 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.